HBM HOLDINGS-B(02142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02142 HBM HOLDINGS-B

Not Yet Opened 04-16 16:08:12

14.790

+0.310

+2.14%

High14.820	Low14.210	Vol4.49M
Open14.520	D1 Closing14.480	Amplitude4.21%
Mkt Cap12.87B	Tradable Cap12.87B	Total Shares870.00M
T/O65.45M	T/O Rate0.52%	Tradable Shares870.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"HBM HOLDINGS-B","latestPrice":14.79,"timestamp":1776326892003,"preClose":14.48,"halted":0,"volume":4487280,"delay":0,"changeRate":0.021408839779005435,"floatShares":869999999,"shares":869999999,"eps":0.8608478568801308,"marketStatus":"Not Yet Opened","change":0.31,"latestTime":"04-16 16:08:12","open":14.52,"high":14.82,"low":14.21,"amount":65449171,"amplitude":0.042127,"askPrice":14.79,"askSize":63000,"bidPrice":14.74,"bidSize":177000,"shortable":3,"etf":0,"ttmEps":0.8608478568801308,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776389400000},"marketStatusCode":0,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":14.48,"openAndCloseTimeList":[[1776303000000,1776312000000],[1776315600000,1776326400000]],"volumeRatio":0.9166049404830884,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142","defaultTab":"news","newsList":[{"id":"2627262919","title":"Harbour Biomed Appoints DR. Adam Zong as President","url":"https://stock-news.laohu8.com/highlight/detail?id=2627262919","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627262919?lang=en_us&edition=fundamental","pubTime":"2026-04-16 15:20","pubTimestamp":1776324024,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA45GX1G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627186262","title":"Press Release: Harbour BioMed Appoints Dr. Adam Zong as President","url":"https://stock-news.laohu8.com/highlight/detail?id=2627186262","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627186262?lang=en_us&edition=fundamental","pubTime":"2026-04-16 15:20","pubTimestamp":1776324000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, April 16, 2026 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. Adam Zong as President. Dr. Zong will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: \"We are very pleased to welcome Dr. Adam Zong to our executive team. His extensive leadership experience across global biopharma organizations and his strong track record in portfolio strategy and business development will be valuable as we continue to advance our innovative pipeline. We look forward to working with him to further strengthen our portfolio and enhance our global partnership.\". Harbour BioMed  is a global biopharmaceutical company committed to the d","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK1583","BK1574","02142","R","BK1161","BK4604","BK4022","BK4585","03160","BK4099","BK4588","BK4232","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168656666","title":"HBM Holdings Reports Marginal Share Increase and Confirms Public-Float Compliance for March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1168656666","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168656666?lang=en_us&edition=fundamental","pubTime":"2026-04-09 23:02","pubTimestamp":1775746927,"startTime":"0","endTime":"0","summary":"HBM Holdings Limited released its Monthly Return for Equity Issuer for the period ended 31 March 2026, detailing minor changes in its share capital structure and confirming full compliance with Hong...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625614180","title":"Assessing HBM Holdings (SEHK:2142) Valuation After Strong 2025 Results And HBM9378 Clinical Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2625614180","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625614180?lang=en_us&edition=fundamental","pubTime":"2026-04-05 05:33","pubTimestamp":1775338391,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) has drawn fresh investor attention after reporting full year 2025 earnings, with sales of US$157.98 million and net income of US$91.33 million, alongside clinical and licensing progress for HBM9378.\nSee our latest analysis for HBM Holdings.\nThe recent earnings release and clinical updates appear to have coincided with a strong 7 day share price return of 14.48% and a 30 day share price return of 23.89%, building on a 1 year total shareholder return of 91.66% and a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/assessing-hbm-holdings-sehk2142-valuation-after-strong-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/assessing-hbm-holdings-sehk2142-valuation-after-strong-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4168","HBM","BK1574","BK1161","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624196865","title":"HBM Holdings (SEHK:2142) Net Margin Surge Challenges Bearish Earnings Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2624196865","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624196865?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:26","pubTimestamp":1775046404,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) just posted its FY 2025 first half scorecard, reporting revenue of US$101.3 million and basic EPS of US$0.09, with management highlighting very large year over year earnings growth over the last 12 months. The company has seen revenue move from US$23.7 million and US$14.4 million in the first and second halves of FY 2024 to US$101.3 million in the first half of FY 2025, while basic EPS shifted from roughly US$0.002 in each FY 2024 half to just over US$0.09, setting up...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-net-margin-surge-challenges-bearish-ea","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-net-margin-surge-challenges-bearish-ea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02142","BK1583","BK4168","HBM","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168101385","title":"Stock Track | HBM HOLDINGS-B Soars 5.04% Intraday Following Employee Share Award Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=1168101385","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168101385?lang=en_us&edition=fundamental","pubTime":"2026-04-01 11:31","pubTimestamp":1775014309,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B's stock price surged 5.04% during intraday trading on Wednesday, marking a significant upward movement for the company's shares.The price movement follows the company's announcement...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624055611","title":"HBM Holdings grants 103,000 nil-price share awards to employee","url":"https://stock-news.laohu8.com/highlight/detail?id=2624055611","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624055611?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:10","pubTimestamp":1774995035,"startTime":"0","endTime":"0","summary":"HBM Holdings granted 103,000 nil-cost share awards under its share award scheme on March 31, 2026.Shares were priced at HK$13.10 on grant date.Vesting schedule sets 25% to vest on Dec. 31, 2027.Another 25% is slated to vest on Dec. 31, 2028.Remaining 50% is set to vest on Dec. 31, 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 31, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL5kjgcG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114539082","title":"HBM HOLDINGS-B (02142) Grants 103,000 Share Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=1114539082","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114539082?lang=en_us&edition=fundamental","pubTime":"2026-03-31 23:48","pubTimestamp":1774972094,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) announced that on March 31, 2026, pursuant to the share award scheme adopted by shareholders on November 23, 2020, the company granted 103,000 share awards to a qualified participant. The grant is subject to acceptance by the grantee.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172631863","title":"Stock Track | HBM HOLDINGS-B Soars 5.28% Intraday on Strong 2025 Financial Results with Revenue Tripling and Profit Surging 33-Fold","url":"https://stock-news.laohu8.com/highlight/detail?id=1172631863","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172631863?lang=en_us&edition=fundamental","pubTime":"2026-03-31 09:55","pubTimestamp":1774922109,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B's stock soared 5.28% during intraday trading on Tuesday, following the release of its exceptional full-year 2025 financial results.The biopharmaceutical company reported that its total...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106729001","title":"HBM HOLDINGS-B (02142) Reports 2025 Financial Results with USD 92.22 Million After-Tax Profit, Surging Approximately 32.63-Fold","url":"https://stock-news.laohu8.com/highlight/detail?id=1106729001","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106729001?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:52","pubTimestamp":1774882347,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) announced its 2025 financial results, revealing revenue of approximately USD 158 million, a year-on-year increase of 314.63%. The annual profit reached USD 92.22 million,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345769","title":"Hbm Holdings - FY Profit US$92.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345769?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:54","pubTimestamp":1774878867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I137:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1161","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345068","title":"HBM FY25 profit jumps to US$ 92 million; revenue more than tripled to US$ 160 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345068","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345068?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:54","pubTimestamp":1774878867,"startTime":"0","endTime":"0","summary":"HBM Holdings posted profit of US$ 92 million for year ended Dec. 31, 2025, versus US$ 2.7 million a year earlier.Revenue surged 314.6% to US$ 160 million, driven by higher molecule license revenue tied to strategic collaborations and new out-licensing.Basic earnings per share rose to US$ 0.12, while cash and cash equivalents climbed to US$ 400 million.R&D costs increased to US$ 40 million as programs advanced, while administrative expenses expanded to US$ 24 million on higher employee and professional costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLbk1yM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","LU0997586432.USD","LU0738911758.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1153584641.USD","LU2114397693.USD","LU0321505868.SGD","LU1481599808.USD","LU0784385170.HKD","LU1057294990.SGD","BK4532","LU2125909247.SGD","IE00BKPKM643.USD","LU1670711123.USD","LU0784385840.USD","LU2242652126.USD","LU0823416689.USD","LU0887340254.USD","LU1093756325.SGD","03165","LU2279689827.SGD","AZN.UK","LU0225284248.USD","LU0122379950.USD","LU1496350502.SGD","LU0211326839.USD","LU0061475181.USD","LU0976567544.SGD","LU0432979614.USD","LU2468319806.SGD","SG9999001176.USD","LU1046234339.USD","BMY","LU0345777659.USD","LU1291159041.SGD","LU1093756168.USD","IE0034235188.USD","LU1104425308.USD","LU2089284900.SGD","LU0972486137.USD","LU0661504455.SGD","IE0009355771.USD","LU1267930573.SGD","LU1880407215.USD","LU0011850046.USD","SGXZ57979304.SGD","LU0345777147.USD","IE00BFXG1179.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345052","title":"Press Release: Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345052","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345052?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:54","pubTimestamp":1774878840,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced its financial results for the year ended December 31, 2025.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: \"2025 marked a pivotal year for Harbour BioMed as we entered the third phase of our strategic evolution, with a clear roadmap toward our 2028 vision of becoming a global leading platform-based biopharmaceutical group.The Company's strategy is powered by three integrated growth engines. These include building a global leading AI-driven antibody discovery 'new infrastructure' through Nona Biosciences, expanding global partnerships through platform-based collaborations with multinational pharmaceutical companies, and unlocking the global value of its mid- to late-stage pipeline in immunology,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","R","MSS","BK1583","LU0456854461.SGD","BK4205","BK4097","02142","BK4213","BK1161","ORR","BK4232","OS","BK1574","CRC","BK4006","BK4590","TSLP","BK4233","BK4113","HCC","NEN","LU0266512127.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622827386","title":"HBM Holdings (SEHK:2142) Valuation After Positive HBM9378 Trial Data And New Regulatory And Licensing Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2622827386","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622827386?lang=en_us&edition=fundamental","pubTime":"2026-03-28 16:08","pubTimestamp":1774685283,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed reported positive first in human Phase I data for HBM9378, a TSLP targeting antibody, along with new regulatory milestones and an expanded global licensing arrangement.\nSee our latest analysis for HBM Holdings.\nThose trial results appear to have reignited interest in the shares, with a 1 day share price return of 6.22% lifting HBM Holdings to HK$12.64 and adding to a 1 year total shareholder return of 37.69%. The 3 year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-after-positive-hbm9378-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-valuation-after-positive-hbm9378-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02142","HBM","LU2065732104.USD","PRGS","BK1574","DCF","BK4097","BK1161","BK4168","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117782838","title":"Hong Kong Stocks Surge as TSLP Antibody Therapy Phase I Trial Results Published","url":"https://stock-news.laohu8.com/highlight/detail?id=1117782838","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117782838?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:06","pubTimestamp":1774335978,"startTime":"0","endTime":"0","summary":"Significant gains were observed for SKB BIO-B (06990) and HBM HOLDINGS-B (02142) during afternoon trading. At the time of writing, SKB BIO-B had risen by 7.34% to HK$426.8, while HBM HOLDINGS-B...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","06990","02142","VXUS","BK1574","BK4588","LU0196878994.USD","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621726337","title":"Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2621726337","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621726337?lang=en_us&edition=fundamental","pubTime":"2026-03-23 11:15","pubTimestamp":1774235736,"startTime":"0","endTime":"0","summary":"Harbour BioMed reported online publication of first-in-human Phase I results from a randomized, double-blind, placebo-controlled single-ascending-dose trial of HBM9378 , a TSLP-targeting monoclonal antibody.The study enrolled 50 healthy adults across five cohorts , with eight participants receiving HBM9378 and two receiving placebo in each cohort.Treatment-emergent adverse events were reported as comparable between HBM9378 dose groups and placebo, and no injection site reactions were observed.Pharmacokinetic results included a median Tmax range of 4.05 to 14.1 days and a mean half-life range of 55 to 65.8 days.Anti-drug antibodies were reported in 5%  of participants who received HBM9378, with no clinical correlate or impact on drug exposure.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2CC4jY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620621166","title":"Harbour BioMed appoints Jenny Xie as chief scientific officer for immunology","url":"https://stock-news.laohu8.com/highlight/detail?id=2620621166","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620621166?lang=en_us&edition=fundamental","pubTime":"2026-03-19 14:42","pubTimestamp":1773902567,"startTime":"0","endTime":"0","summary":"Harbour BioMed appointed Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.Jenny Xie will be based in Shanghai and report to CEO Jingsong Wang.Her responsibilities include leading the company’s external innovation strategy in immunology and overseeing the Harbour BioMed-AstraZeneca Innovation Lab in Beijing.Before joining Harbour BioMed, she was Executive Director and Head of Discovery Immunology at Bristol Myers Squibb.She previously held scientific leadership roles at Merck.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL8dwdWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565080.SGD","LU1267930813.SGD","LU2242652126.USD","LU0965508806.USD","BK4007","LU1481599808.USD","LU0130102774.USD","LU0985320562.USD","LU2125909593.SGD","LU2468319806.SGD","SG9999002232.USD","SG9999002224.SGD","LU1003076772.USD","LU0784385170.HKD","LU1051770623.HKD","LU0061475181.USD","LU1430594728.SGD","LU2125909247.SGD","LU2091194634.USD","LU2360032135.SGD","LU0920840948.USD","LU0456855351.SGD","LU1487256676.USD","LU0965509010.AUD","LU0949170772.SGD","LU0557290698.USD","LU1880407132.USD","BK4532","LU1093756325.SGD","LU0098860793.USD","LU0211326839.USD","IE00BKPKM643.USD","LU0823416689.USD","LU1989771016.USD","LU2023250504.SGD","LU0784385840.USD","LU1267930490.SGD","LU1670710661.SGD","LU1003077747.HKD","LU0211328371.USD","LU0211326755.USD","LU1323610961.USD","LU0648001328.SGD","LU1066051225.USD","LU1119994496.HKD","LU1061106388.HKD","LU1104425308.USD","LU1880407215.USD","LU0047473722.SGD","IE00B3T34201.USD","LU0545039389.USD","BK4559","LU0757432116.USD","LU1941712264.USD","LU1078025761.USD","LU0887340254.USD","LU0526926950.USD","IE00BFTCPJ56.SGD","SG9999015358.SGD","LU0208291251.USD","LU1084165304.USD","LU1153585028.USD","LU0225284248.USD","LU2539964713.USD","SG9999014575.USD","BK4550","BK1574","LU1066051498.USD","SG9999014559.SGD","LU0868494708.USD","LU1074936037.SGD","LU1868836757.USD","LU1170363599.USD","LU0058720904.USD","LU0575583348.USD","LU1064927863.SGD","IE00BLSP4239.USD","LU0823399737.USD","LU0942090050.USD","LU2089283258.USD","LU0868494617.USD","LU1929549753.HKD","IE00B1BXHZ80.USD","LU1868836591.USD","LU0861579265.USD","BK4534","LU0234572021.USD","LU0997586432.USD","LU1291159041.SGD","LU1037948541.HKD","IE0034235188.USD","LU0708994859.HKD","LU1814569148.SGD","LU1069347547.HKD","LU0306807586.USD","BK5011","SG9999001440.SGD","LU1066053197.SGD","LU1670710588.SGD","02142","LU0792757196.USD","LU1019632923.USD","LU1481600234.SGD","LU1162221912.USD","SG9999014542.SGD","IE0009355771.USD","LU1496350171.SGD","LU0920783379.SGD","LU1301847155.USD","LU2279689827.SGD","BK1583","LU0238689110.USD","LU0106261372.USD","LU0661504455.SGD","LU1923622614.USD","LU1883839398.USD","LU1934455277.USD","LU0052756011.USD","LU1496350502.SGD","BK4516","LU0320765489.SGD","LU1201861249.SGD","LU2293690082.USD","LU1261432733.SGD","LU1093756168.USD","LU0321505439.SGD","LU1032466523.USD","LU2108987350.USD","LU0158827948.USD","LU0237698245.USD","LU0171293334.USD","LU1585245621.USD","LU1868837136.USD","LU0784384876.USD","IE00BBT3K403.USD","LU1267930573.SGD","SG9999013999.USD","LU1934455194.USD","LU1046234339.USD","LU0345777147.USD","LU2023251221.USD","LU0827474353.SGD","LU1989772923.USD","LU1718418525.SGD","LU1699723380.USD","BK4588","LU1035773651.USD","LU1868836914.USD","LU0289739699.SGD","LU0965509101.SGD","LU0857590862.USD","LU0965509283.SGD","LU1868837300.USD","LU2133065610.SGD","LU0320765646.SGD","SG9999015341.SGD","LU0964806797.USD","IE000M9KFDE8.USD","LU0432979614.USD","SGXZ57979304.SGD","LU0310799852.SGD","BK4581","LU0345777659.USD","LU1116320901.HKD","LU0265550946.USD","LU0963555726.SGD","LU1267930227.SGD","LU0477156953.USD","LU2433249047.HKD","IE00BJT1NW94.SGD","LU0096364046.USD","IE00BJJMRZ35.SGD","LU2361045086.USD","LU0985481810.HKD","LU0211331839.USD","LU1670711040.USD","LU2106854487.HKD","LU0011850046.USD","LU2112291526.USD","LU0310800965.SGD","LU2293690249.USD","LU1153584641.USD","LU0310800379.SGD","LU2324357040.USD","LU1037948897.HKD","LU0321505868.SGD","LU2023250843.SGD","LU0969580561.USD","LU0784383803.USD","LU0114720955.EUR","LU0553294199.USD","LU0889566641.SGD","LU0972486137.USD","LU0949170426.SGD","IE00BN8TJ469.HKD","LU0070302665.USD","03165","LU1019634622.SGD","LU2089284900.SGD","BK4585","LU2461242641.AUD","LU0306806265.USD","LU2361044865.SGD","LU0976567544.SGD","LU0130517989.USD","LU2125154935.USD","IE00B2B36J28.USD","LU0128525929.USD","IE00BLSP4452.SGD","LU0496365809.HKD","LU0738911758.USD","LU0960981461.USD","LU2089984988.USD","LU1057294990.SGD","IE0002141913.USD","LU0266013472.USD","IE00BFXG1179.USD","LU0128525689.USD","LU0390134368.USD","LU0882574055.USD","LU1023059063.AUD","LU1934455863.HKD","LU2125154778.USD","LU1989772840.SGD","LU2242646821.SGD","LU0499090636.EUR","LU0980610538.SGD","LU1941712348.USD","LU1974910355.USD","LU0267386448.USD","LU1571399168.USD","LU0265550359.USD","LU0077335932.USD","LU1015430645.USD","IE00B4R5TH58.HKD","LU0957799991.USD","LU1066051811.HKD","LU2361044949.HKD","BK4533","SG9999001176.USD","LU0122379950.USD","SG9999001176.SGD","LU0047473722.EUR","LU0203345920.USD","LU1983299246.USD","LU1917777945.USD","LU1670711123.USD","IE00BSNM7G36.USD","BK1161","LU0640478417.SGD","LU1116320737.USD","SG9999014567.USD","LU0006306889.USD","LU0029864427.USD","LU0203347892.USD","LU0211327993.USD","LU2114397693.USD","LU0225771236.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620665211","title":"Harbour Biomed Appoints DR. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2620665211","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620665211?lang=en_us&edition=fundamental","pubTime":"2026-03-19 14:42","pubTimestamp":1773902550,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA6JCQRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150719087","title":"HBM Holdings-B (02142) Schedules 30 March 2026 Board Meeting to Approve FY 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1150719087","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150719087?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:41","pubTimestamp":1773826891,"startTime":"0","endTime":"0","summary":"HBM Holdings Limited (stock code: 02142) has announced that its board of directors will convene on 30 March 2026 to review and approve the Group’s annual results for the financial year ended 31...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620295239","title":"HBM Holdings schedules board meeting to approve annual results for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2620295239","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620295239?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:38","pubTimestamp":1773826695,"startTime":"0","endTime":"0","summary":"HBM will hold a board meeting on 30 March 2026 to consider and approve the group’s annual results for the year ended 31 December 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5fsTT0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","02142"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0804},{"period":"1month","weight":0.2083},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.1564},{"period":"1year","weight":1.0599},{"period":"ytd","weight":0.2163}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0203},{"period":"3month","weight":-0.0168},{"period":"6month","weight":0.0454},{"period":"1year","weight":0.2535},{"period":"ytd","weight":0.0298}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.5,"avgChangeRate":0.032599},{"month":5,"riseRate":0.6,"avgChangeRate":0.040454},{"month":6,"riseRate":0.2,"avgChangeRate":-0.066065},{"month":7,"riseRate":0.4,"avgChangeRate":0.030357},{"month":8,"riseRate":0.2,"avgChangeRate":0.005624},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065735},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"HBM HOLDINGS-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HBM HOLDINGS-B(02142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HBM HOLDINGS-B(02142) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HBM HOLDINGS-B,02142,HBM HOLDINGS-B股票,HBM HOLDINGS-B股票老虎,HBM HOLDINGS-B股票老虎国际,HBM HOLDINGS-B行情,HBM HOLDINGS-B股票行情,HBM HOLDINGS-B股价,HBM HOLDINGS-B股市,HBM HOLDINGS-B股票价格,HBM HOLDINGS-B股票交易,HBM HOLDINGS-B股票购买,HBM HOLDINGS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HBM HOLDINGS-B(02142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HBM HOLDINGS-B(02142) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}